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Experimental Lyme arthritis is an inflammatory arthritis caused by infection of mice with
the spirochete, Borrelia burgdorferi. It recapitulates many of the disease parameters
seen in human patients with Lyme arthritis, and thus serves as a model system for the
investigation of disease pathogenesis. While much progress has been made in defining
components of the immune response to Borrelia infection, an overall understanding of
the host response leading to arthritis resistance or susceptibility remains elusive. In this
review, we will focus on recent advancements of our understanding of the roles of
eicosanoids as inflammatory mediators in the regulation of experimental Lyme arthritis.
Eicosanoids, such as PGE2 and LTB4, are powerful regulators of inflammatory responses
and thus may be important mediators of Lyme arthritis.
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INTRODUCTION
Lyme disease is a major source of morbidity due to the high inci-
dence of rheumatic, cardiovascular, and neurologic complications
that follow infection with the etiologic agent, Borrelia burgdor-
feri (Barbour and Fish, 1993). B. burgdorferi is transmitted to
the mammalian host through the bite of an infected Ixodes tick
(Burgdorfer et al., 1982). Acute disease is characterized by a classic
enlarging bulls-eye rash called erythema migrans, which resolves
on its own if left untreated (Steere et al., 2004). Twenty percent
of individuals, despite being infected, will remain disease free fol-
lowing resolution of their skin rash. If not treated with antibiotics
at this stage, however, most infected individuals will go on to
develop secondary complications including carditis, arthritis, or
neurological disease (Steere et al., 2004). Subsets of individuals
who receive appropriate antibiotic therapy still develop recurrent
episodes of chronic joint inflammation up to years after receiving
appropriate treatment (Steere et al., 2004; Iliopoulou and Huber,
2010). The genetic components and/or immune parameters that
predispose individuals to develop chronic symptoms associated
with Lyme disease or to remain disease free are unclear and the
subject of ongoing research (Steere et al., 2004).
Experimental Lyme arthritis is the murine model system of
Lyme arthritis and recapitulates many of the disease parame-
ters seen in patients with Lyme arthritis. The murine model
is an inflammatory arthritis and requires the presence of live
spirochetes within the joint for disease development. Arthritis
development, however, is genetically controlled resulting in Lyme
arthritis-resistant and -susceptible mouse strains (Barthold et al.,
1990). C57BL/6 (B6) mice are the most commonly used Lyme
arthritis-resistant strain, while C3H/He (C3H) mice are the
most commonly used Lyme arthritis-susceptible strain. Infection
of susceptible mouse strains with B. burgdorferi results in the
development of arthritis which peaks around 3–4 weeks post-
infection, and then spontaneously resolves over the next few
weeks (Barthold et al., 1996). While live spirochetes are required
for disease development, their absolute numbers within the joint
do not correlate with arthritis severity. Lyme arthritis-resistant
and -susceptible mouse strains can harbor equivalent numbers
of spirochetes within their joints, yet maintain their distinct dis-
ease phenotypes (Brown and Reiner, 1998; Ma et al., 1998).
This defines experimental Lyme arthritis as an immunopathol-
ogy. Disease development in mice is driven primarily by innate
immunity, since arthritis-susceptible mice devoid of T and B cells
retain their disease susceptibility (Schaible et al., 1989; Brown and
Reiner, 1999). Arthritis resolution, on the other hand, appears
to be mediated by the production of anti-Borrelia antibodies and
spirochete clearance from the joints (Barthold et al., 1996). While
infection of mice with B. burgdorferi is a useful model for study-
ing disease pathogenesis, it is currently unclear if similar disease
mechanisms are operational during the immune response to B.
burgdorferi infection in humans.
EICOSANOIDS IN LYME ARTHRITIS
Eicosanoids are 20-carbon fatty acids derived from the
metabolism of arachidonic acid (AA) and are powerful mediators
of inflammation (Stables and Gilroy, 2011). Upon activation
of immune cells, AA is released from cellular membrane
stores primarily via the activity of cytosolic phospholipase
A2 (cPLA2). The released AA is then metabolized to various
biological mediators via three primary enzymatic pathways:
cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome
P450 (CYTP) (see Figure 1). Each pathway contains additional
metabolite-specific enzymatic steps resulting in a wide variety
of bioactive compounds (e.g., prostaglandins, leukotrienes, etc).
Not all inflammatory cells express all three pathways and there is
considerable variation in the production of specific metabolites.
In addition, there appears to be a predisposition for certain cells
to produce specific metabolites, e.g., macrophages tend to make
high levels of prostaglandin (PG)E2 while neutrophils tend to
produce high levels of leukotriene (LT)B4, although they are each
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FIGURE 1 | Simplified eicosanoid metabolic pathway. Upon tissue damage or infection arachidonic acid (AA) is released frommembrane stores by the activity
of cytosolic phospholipase 2. The free AA is then acted upon by the primary metabolic enzymes (green) and converted to numerous bioactive compounds (blue).
capable of making both of these metabolites when stimulated
under certain conditions in vitro (Kihara et al., 2014). Although
eicosanoids are powerful regulators of inflammation, in general
their role in mediating an immune response to infection is
incompletely understood.
Since experimental Lyme arthritis is an inflammatory arthri-
tis that develops and then spontaneously resolves, it is an ideal
model to study how eicosanoids regulate the induction and reso-
lution of an inflammatory response. COX-2 is an inducible gene
expressed primarily in immune cells and is responsible for the
production of PG during an inflammatory response (Mitchell
et al., 1993). Non-steroidal anti-inflammatory drugs (NSAIDs,
e.g., aspirin, ibuprofen) are powerful inhibitors of the COX
enzymes, with newer drugs (e.g., Celebrex) preferentially inhibit-
ing COX-2. In an initial study of the role of COX-2 in the
host immune response to B. burgdorferi infection, the expres-
sion of COX-2 was found to increase in the joints of infected
C3H mice by day 14 post-infection and remain elevated through
day 60 (Anguita et al., 2002). Furthermore, treatment of infected
mice with a COX-2-specific inhibitor, MF-tricyclic, decreased
arthritis severity scores compared to untreated controls at day
14 post-infection without altering T or B cell responses. These
results suggested that NSAIDs or other COX-2-specific inhibitors
might be effective treatments for Lyme arthritis, possibly with-
out compromising spirochete clearance. We followed up on these
results and conducted experiments using two commercially avail-
able COX-2-specific inhibitors, rofecoxib (Vioxx) and celecoxib
(Celebrex), as well as C3H COX-2 knockout mice (Blaho et al.,
2008). In contrast to the previous study, we found no effect of
COX-2 deletion or inhibition on the development of experimen-
tal Lyme arthritis at a number of time-points throughout the
infection. We did, however, find a significant delay or inhibi-
tion of arthritis resolution in mice devoid of COX-2 activity. In
agreement with the previous study, we found that COX-2 inhi-
bition or deletion had little effect on Borrelia-specific antibody
production, and clearance of spirochetes from tissues appeared
to occur at the same rate in COX-2 deficient and control mice.
This demonstrated that arthritis resolution could be uncoupled
from spirochete clearance from the joint, andmay have important
implications for patients with persistent arthritis despite seem-
ingly effective antibiotic therapy. In addition, NSAID therapy to
counteract joint pain and swelling during acute Lyme arthritis
may be contraindicated and lead to a prolongation of arthritis
symptoms. Only a single time point (14 days post-infection) was
reported by Anguita et al. which suggested a delay in arthritis
development. We did not see a delay in arthritis development in
our study, but this may be due to differences in intradermal vs.
footpad routes of infection. Further work in this area is required
to define the roles of COX-2 metabolites on the development and
resolution of experimental Lyme arthritis.
COX-2 is an inducible enzyme that when activated, produces
metabolites that are responsible for inciting inflammation and
vasodilation (Stables and Gilroy, 2011). The most prominent of
these metabolites are PGE2 and PGD2. Patients diagnosed with
arthritis, infectious or immune mediated, are frequently treated
with NSAIDs. These drugs are designed to be COX-2 specific to
combat the inflammation associated with the activation of the
COX pathway. In the experimental Lyme arthritis model, inhi-
bition of COX-2 through gene deletion resulted in milder ankle
swelling and arthritis that failed to resolve (Blaho et al., 2008).
Histologically, neutrophilic infiltration was still present to the
same degree in the COX-2−/− mice as in their wild-type coun-
terparts. PGE2 and PGD2 levels in the tissue of uninfected and
infected COX-2−/− mice were decreased, as expected. Since PGs
are responsible for vascular tone, this could explain the attenu-
ation of swelling resulting from their failure to vasodilate to the
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same degree as wild-type mice. Infected COX-2−/− mice also
had unexpected decreased levels of 5-LOX metabolites, poten-
tially contributing to the prolonged inflammatory response seen
in these mice (as discussed in the following paragraph).
We have also completed a study of the role of 5-LOX in the
development of experimental Lyme arthritis (Blaho et al., 2011).
This enzyme is primarily expressed in neutrophils and catalyzes
the conversion of AA to LTB4 and the cysteinyl leukotrienes
(LTC4, D4, and E4). LTB4 is a powerful neutrophil chemoattrac-
tant and plays an important role in the initiation of arthritis in the
K/BxN serum transfer model (Kim et al., 2006), and in collagen-
induced arthritis (CIA) (Shao et al., 2006). Both K/BxN serum
transfer and CIA arthritis models are experimental autoimmune
models of rheumatoid arthritis. Serum from K/BxN mice con-
tain autoantibodies against glucose 6-phosphate isomerase, while
the CIA model involves the induction of cross-reactive antibod-
ies to mouse collagen. Both models develop polyarthritis and
can be induced in certain mouse strains by the passive transfer
of autoimmune serum. Inhibition of 5-LOX activity or inhibi-
tion of LTB4 signaling through its high-affinity receptor, BLT1,
can inhibit the development of arthritis in both of these models.
Following infection of C3H mice with B. burgdorferi, we found
increased expression of mRNA for 5-LOX and its accessory pro-
tein, five lipoxygenase activating protein in joint tissue, as well
as increased production of LTB4 (Blaho et al., 2011). Infection
of C3H 5-LOX knockout mice, in contrast to the K/BxN or CIA
arthritis models, led to an earlier development of Lyme arthritis.
In addition, similar to what was seen in the COX-2 deficient mice,
arthritis resolution was delayed or inhibited in the 5-LOX defi-
cient mice as compared to wild type C3H controls. Production of
Borrelia-specific IgG was decreased in the C3H 5-LOX knockout
mice, but spirochete clearance from tissues appeared to be simi-
lar to controls, indicating the amount of antibody produced was
adequate to mediate spirochete clearance.
Products from the 5-LOX metabolic pathway, especially LTB4,
have been shown to have a significant impact on macrophage
phagocytosis and killing of various pathogens (Serezani et al.,
2005). Figure 2 depicts how a failure in LTB4 production by neu-
trophils might influence arthritis resolution. In vitro, we demon-
strated that spirochete uptake and killing by 5-LOX-deficient
neutrophils wasmostly intact, while 5-LOX-deficient macrophage
uptake of B. burgdorferi and apoptotic neutrophils was signif-
icantly impaired (Blaho et al., 2011). These results suggested
that neutrophils may be the primary cells responsible for spiro-
chete clearance, but that macrophage clearance of apoptotic neu-
trophils may be important for the timely and efficient induction
of arthritis resolution and return of the tissue to homeostasis.
Further work in this area is required to identify the mechanisms
involved, but macrophage uptake of apoptotic cells has been
shown to induce their phenotypic change from pro-inflammatory
to anti-inflammatory and promote resolution of inflammation
(Freire-de-Lima et al., 2006).
EICOSANOID PRODUCTION DURING INFECTION
To gain a more complete understanding of the production of
eicosanoids in the arthritic joint during B. burgdorferi infec-
tion, we conducted the first published comprehensive lipidomic
study of infected tissue (Blaho et al., 2009a). Additional lipidomic
studies using other infectious diseasemodels have since been pub-
lished, providing further insight into the impact of eicosanoids
on immune function and as targets for future therapeutics (Tam,
2013). In our study, joint tissue from arthritis-resistant DBA/2,
and -susceptible C3H mice were analyzed for the production of
104 unique lipid species in the eicosanoid metabolome during
the development and resolution phases of experimental Lyme
arthritis. Several of the eicosanoid pathways between an arthritis-
resistant and susceptible strain were different at baseline as well
as during B. burgdorferi infection, and these differences may drive
genetic predispositions to arthritis resistance or susceptibility.
Upon infection with B. burgdorferi, alterations in the produc-
tion of metabolites from all three eicosanoid pathways became
evident. Specific strain differences noted were elevation in 5,6
epoxyeicosatrienoic acid (EET), and lower PGD2and protectin
D1 (PD1) levels in DBA/2 mice as compared to C3H mice. Both
strains exhibited elevations in PGE2 and a decrease in 11,12 EET.
PGE2 and PGD2 are metabolites derived from the COX path-
way and are considered primarily pro-inflammatory. Although
PGE2 becomes elevated in both strains, PGD2 did not signif-
icantly increase from basal levels in DBA/2 mice. The lack of
elevation of PGD2 in arthritis-resistant DBA/2 mice may be one
potential factor contributing to the observed strain susceptibility
differences.
The CYTP pathway is responsible for producing EETs. The
overall function of EETs is vasodilation, angiogenesis, and cel-
lular proliferation (Fang et al., 1996; Pozzi et al., 2005; Blaho
et al., 2009a; Stables and Gilroy, 2011). The ratio of 5,6 EET was
higher in DBA/2 mice as compared to C3H mice at basal levels
and after B. burgdorferi infection (Blaho et al., 2009a). 5,6 EET
specifically causes vasodilation and is a potent neo-vascular agent
(Pozzi et al., 2005). An increase in vessel formation and blood
flow at the site of inflammation due to 5,6 EET could improve
the clearance of Borrelia bacteria in DBA/2 mice as compared to
C3H mice, although no differences in bacterial tissue loads were
detected. The most significant change within the CYTP path-
way in both strains was a decrease in 11,12 EET as compared to
other EETs and dihydroxyeicosatrienoic acid (DHET) molecules
(Blaho et al., 2009a). Vascular cell adhesion molecule expression
is down-regulated in the presence of 11,12 EET in experimentally
inflammed murine carotid arteries, which prevented the recruit-
ment of leukocytes to the site of inflammation (Node et al., 1999).
It is hypothesized that 11,12 EET acts as an anti-inflammatory
agent in a similar fashion to counter balance the other pro-
inflammatory mediators in Lyme arthritis, however, more work
is needed in this area.
Protectin D1 (PD1) is a product of the metabolism of the
omega-3 fatty acid, docosahexaenoic acid (DHA), via the 12/15-
LOX pathway. It is associated with anti-inflammatory and pro-
resolution properties, including the inhibition of neutrophil
influx (Levy et al., 2007; Stables and Gilroy, 2011). In Lyme
arthritis, PD1 was significantly elevated in C3H mice, but not
in DBA/2 mice (Blaho et al., 2009a). The stable metabolite of
PD1 and resolvins, 17-HDoHE, was elevated earlier in infection
(day 14) in C3H mice as compared to DBA/2 mice (day 28).
Based on this experimental finding, we hypothesize that C3H
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FIGURE 2 | Possible role for LTB4 in regulating resolution of
inflammation. (A) Neutrophils are recruited to the infected joint and
engulf B. burgdorferi. Neutrophils produce LTB4 which stimulate
macrophage phagocytosis of apoptotic neutrophils (efferocytosis) and their
switch to an anti-inflammatory/pro-resolution phenotype promoting a
return to homeostasis. (B) Failure of neutrophils to produce LTB4 results
in inefficient macrophage phagocytosis and failure to clear apoptotic
neutrophils in a timely manner. Apoptotic neutrophils in the tissue
proceed to necrosis and release their cytoplasmic contents causing
tissue damage and promoting continued inflammation. Similarly,
macrophages that fail to engulf apoptotic cells remain in a
pro-inflammatory state and promote prolonged inflammation.
mice may have a higher threshold of tolerance for PD1, requir-
ing higher levels of PD1 to produce the same effects as in DBA/2
mice. In addition, the susceptibility of C3H mice to Lyme arthri-
tis could be explained by the altered metabolism of up-stream
products supported by the appearance of 17-HDoHE earlier in
C3H as compared to DBA/2 mice. Further studies are required to
determine the exact role these metabolites play in Lyme arthritis
resolution.
MANIPULATING THE EICOSANOID PROFILE
Omega-3 polyunsaturated fatty acids (n-3 PUFAs) have received
attention for their potential beneficial effects in a vast number of
diseases including dermatitis, rheumatoid arthritis, osteoarthri-
tis, neoplasia, cardiovascular disease, and inflammatory bowel
disease (Dumlao et al., 2012; Shek et al., 2012). The prominent
feature of n-3 PUFAs in these diseases is their anti-inflammatory
effects. A diet rich in n-6 PUFAs (e.g., AA) has been linked to
the development and persistence of various diseases (Shek et al.,
2012). Dietary n-3 PUFAs can compete with AA for incorporation
into cellular membranes and for use as substrates for COX and
LOX enzymes (Lands et al., 1990). Use of n-3 PUFAs as substrates
results in the generation of (n-3) eicosanoids that are generally
less potent than analogous (n-6) eicosanoids (Wada et al., 2007).
However, the role n-6 and n-3 PUFAs play in the face of infec-
tion and how they alter the production of eicosanoids is unclear.
There are conflicting reports regarding the benefits of dietary n-
3 PUFAs modulating the immune system to aid in the recovery
from bacterial pneumonia, while other reports find a detrimen-
tal effect during influenza infection (Shek et al., 2012; Sharma
et al., 2013). We investigated the effect of dietary n-3 and n-6
PUFAs in murine Lyme arthritis (Dumlao et al., 2012). Feeding B.
burgdorferi-infected C3H mice a fish oil diet, rich in n-3 PUFAs,
shifted the eicosanoid profile toward an anti-inflammatory one,
while a soy oil diet, rich in n-6 PUFAs, shifted it toward a pro-
inflammatory profile. Again using a lipidomics approach, we
found more fatty acid (FA) metabolites identified in fish oil fed
mice as compared to soy oil fed mice, with most metabolites
being EPA and DHA derived. Based on previous reports, it would
be expected that a diet rich in n-3 PUFAs would produce an
anti-inflammatory eicosanoid profile. Despite a shift toward anti-
inflammatory eicosanoids in mice fed a n-3 PUFA rich diet in
Lyme arthritis, there was no effect on the clinical observations
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or histological findings between the two different diets (Dumlao
et al., 2012). It is likely there are several factors involved in the
development of arthritis, in addition to the eicosanoid profile.
Also, one caveat to this study was that we did not examine the
resolution phase of the disease process and thus may have missed
the effects of dietary fish oil on arthritis resolution and return to
homeostasis.
EICOSANOID INFLUENCE ON ANTIBODY PRODUCTION
Production of Borrelia-specific antibodies and clearance of spiro-
chetes from the inflamed joint is thought to mediate the res-
olution of Lyme arthritis (Barthold et al., 1996). However, as
discussed above, C3H mice deficient in COX-2 or 5-LOX devel-
oped Lyme arthritis, but failed to resolve their inflammation
despite a seemingly effective antibody response and spirochete
clearance. Thus, we were interested in taking a closer look at the
role eicosanoids might play in antibody responses. Historically
the inhibition of prostaglandin production has been linked to
decreased antibody responses (Roper et al., 2002). The roles of
COX enzymes in antibody production, however, appear to vary
depending on the underlying pathology and mode of stimula-
tion. Deletion of the COX-2 gene in a CIA model resulted in
decreased production of anti-collagen antibodies and markedly
attenuated arthritis development as compared to wild-type and
COX-1 knockout mice (Myers et al., 2000). The effect of COX
inhibition on antibody production in an infectious scenario has
revealed conflicting results. During vaccinia virus infection, dele-
tion of COX-2 resulted in decreased levels of several subclasses of
IgG due to failure of immunoglobulin class-switching (Bernard
et al., 2010). Similarly, pathogen-specific antibody production
was decreased by COX-2 inhibition during Mycobacterium bovis-
induced arthritis (Turull and Queralt, 2000). More recently, our
lab has investigated the effect of COX-2 and COX-1 gene dele-
tion using B. burgdorferi. In this infectious model, COX-2−/−
mice produced comparable antibody levels to infected wild-type
mice. However, infected COX-1−/− mice revealed an inhibi-
tion of immunoglobulin class-switching supported by elevated
IgM and decreased total IgG levels (Blaho et al., 2009b). In
addition, histology revealed defective germinal center forma-
tion in COX-1 deficient mice. The prostaglandin, PGE2, has
been shown to influence the activation and proliferation of lym-
phocytes, and assist in B cell antibody class-switching (Ryan
et al., 2005). We investigated the effect of eicosanoid produc-
tion when COX-1 was inhibited or deleted in vitro and in
vivo. Deletion of COX-1 decreased the production of PGE2 and
PGD2, although not significantly so as compared to infected
wild-type mice in splenic tissue. However, additional eicosanoids
that were significantly decreased were TXB2, PGF1α, PGF2α,
and PGJ2. Inhibition of COX-1 or FP receptor, the recep-
tor for PGF2α, in cultures of B. burgdorferi infected splenic B
cells caused both IgM and IgG production to become signif-
icantly decreased as compared to infected controls. This pro-
vided evidence that other prostaglandins in addition to PGE2
may also be responsible for assisting in antibody production
and class-switching. Experiments evaluating the maturation and
function of B cells in COX-1 inhibited or deleted mice are
needed to further elucidate the mechanism for the failure of
immunoglobulin class-switching identified in B. burgdorferi-
infected mice.
CONCLUSION
Lyme arthritis caused by B. burgdorferi remains a significant dis-
ease in human medicine. The cause for individual susceptibility
to chronic arthritis associated with Lyme disease has yet to be
explained. The use of murine models of Lyme arthritis has pro-
vided significant insight into the pathogenesis and clues into indi-
vidual susceptibility to chronic disease. It is clear that the immune
response and development of Lyme arthritis is complex and mul-
tifaceted. Dysregulation of inflammatory and anti-inflammatory
mediators, in addition to genetics, add to the factors that deter-
mine the ultimate clinical course of disease. Understanding the
interaction of cytokines, chemokines, eicosanoids, and genetic
influences during B. burgdorferi infection will allow improved
treatment for individuals with Lyme arthritis.
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